PDCD1 and hepatocellular carcinoma: Kudo Masatoshi is one of the authors of the milestone CheckMate 040 study (El-Khoueiry et al., 2017), which was the first to confirm the safety and efficacy of the PD-1 inhibitor Nivolumab in advanced HCC.